Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TiGenix

- PMLiVE

Global drug spending will rise by a third to $1.5trn in 2021

However, rate of growth will not match previous years due to pricing and access pressures

- PMLiVE

Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands

dengue fever mosquito

Takeda plans German plant to support dengue vaccine roll-out

Will invest more than €100m in the Singen manufacturing facility

- PMLiVE

Janssen files Stelara follow-up guselkumab in Europe

Trial data shows J&J’s drug is more effective in treating psoriasis than AbbVie’s Humira

- PMLiVE

Takeda gets EU green light for oral myeloma drug

Ninlaro first oral proteasome inhibitor to be registered in Europe

Bristol-Myers Squibb (BMS) building

Opdivo gets green light for Hodgkin lymphoma in Europe

Becomes the first PD-1 inhibitor to receive EU licence in this indication

- PMLiVE

Takeda and Marvel launch IBD superhero squad

The comic book initiative aims to raise awareness of the gastrointestinal disease

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

- PMLiVE

Ready for takeoff?

A new pathway promises expedited approvals for innovative medicines

- PMLiVE

ApotheCom and Continuum Clinical expand strategic partnership

Team up to deliver real-world evidence-based integrated business solutions

- PMLiVE

MHRA launches medicines side effects awareness drive

Creates social media campaign as part of EU-wide initiative

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links